Tempus AI, Inc.
Close on Oct 19, 2026
- Market cap
- $11.74M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | After market close | $382.50M | $0.03 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $348.10M | $-0.71 | $-0.13 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | $367.00M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $334.20M | $-0.46 | $-0.11 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | Before market open | $314.60M | $-0.25 | $-0.22 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $255.70M | $-0.40 | $-0.24 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | $200.00M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | After market close | $180.90M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | $166.00M | $-6.86 | $-0.63 |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | 2026 | $65.00M | Maintained |
| revenue guidance | full year 2026 | $1.60B to $1.61B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Tempus AI filed with the SEC
Tempus Reports Second Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled
Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Tempus Reports First Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Reports Fourth Quarter and Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Tempus Reports Third Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Reports Second Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Tempus Reports First Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Reports Fourth Quarter and Full Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempus Reports Second Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K